Beam Therapeutics Inc.
Price Action
Technical Summary
STAGE 2 UPTRENDBeam Therapeutics Inc. is in a confirmed Stage 2 uptrend, with price holding above all major moving averages and trend structure remaining intact. Relative strength is moderate (RS Rating: 78), indicating performance broadly in line with the market. Earnings growth of 27% provides fundamental context to the price action. Investors should exercise caution due to high volatility (75% annualized), which requires wider risk management.
Trend Template (Minervini)
Price vs Moving Averages
| Period | Value | Spread | Signal |
|---|---|---|---|
| 20 SMA | $31.02 | +14.54% | ABOVE |
| 50 SMA | $30.35 | +17.08% | ABOVE |
| 100 SMA | $28.36 | +25.28% | ABOVE |
| 150 SMA | $28.01 | +26.83% | ABOVE |
| 200 SMA | $27.08 | +31.21% | ABOVE |
Price Performance
Technical Indicators
Risk Profile
Volume Analysis
Earnings Momentum
Growth Trends
Compounded Sales Growth
Compounded Profit Growth
Stock Price CAGR
Return on Equity
Key Metrics
Frequently Asked Questions
Is BEAM in an uptrend right now?
BEAM has a trend score of 4/4 based on Minervini's Stage Analysis. Yes, BEAM is in a Stage 2 uptrend with price above all major moving averages (50, 100, 150, 200 SMA) properly stacked.
Is BEAM overbought or oversold?
BEAM's RSI (14) is 62. The stock is in neutral territory, neither overbought nor oversold.
Is BEAM outperforming the market?
BEAM has a Relative Strength (RS) Rating of 78 out of 99. BEAM is performing about average compared to the market.
Where is BEAM in its 52-week range?
BEAM is trading at $35.53, which is 96% of its 52-week high ($36.88) and 94% above its 52-week low ($15.60).
How volatile is BEAM?
BEAM has a Beta of 2.20 and 52-week volatility of 75%. It's more volatile than the S&P 500 - expect bigger swings.